Metagenomi Therapeutics financials
$1.13−0.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$257.0K | $1.2M | $3.9M | $8.7M | $8.5M | $4.1M | $9.6M | $11.5M | $20.0M | $11.2M |
| Gross profit | -$257.0K | $1.2M | $3.9M | $8.7M | $8.5M | $4.1M | $9.6M | $11.5M | $20.0M | $11.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$28.8M | -$24.6M | -$24.4M | -$22.8M | -$21.0M | -$27.8M | -$20.6M | -$22.4M | -$16.9M | -$29.0M |
| Net income | -$27.5M | -$23.1M | -$22.5M | -$20.4M | -$19.9M | -$25.0M | -$23.4M | -$18.8M | -$10.7M | -$25.1M |
| Net margin | 10693.4% | −1847.7% | −576.0% | −235.5% | −233.9% | −606.7% | −243.4% | −163.0% | −53.7% | −225.4% |
| Diluted EPS | $-0.73 | $-0.61 | $-0.60 | $-0.55 | $-0.54 | $-0.68 | $-0.62 | $-0.51 | $-0.29 | $-1.19 |
| EBITDA | -$27.5M | -$23.3M | -$23.1M | -$21.5M | -$19.7M | -$26.5M | -$19.2M | -$21.0M | -$15.6M | -$27.8M |
| Operating cash flow | -$19.5M | -$21.2M | -$23.5M | -$21.3M | -$21.3M | -$22.8M | -$26.3M | -$26.6M | -$26.3M | -$29.9M |
| Free cash flow | -$19.6M | -$21.2M | -$23.6M | -$21.3M | -$21.4M | -$23.1M | -$26.6M | -$27.8M | -$27.0M | -$30.8M |
| Diluted shares | 37.7M | 37.6M | 37.5M | 37.3M | 37.2M | 37.0M | 37.6M | 36.8M | 36.6M | 21.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.0M | $25.3M | $41.7M | $32.8M | $26.9M | $29.2M |
| Short-term investments | $81.6M | $114.9M | $119.1M | $151.3M | $178.1M | $196.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $173.7M | $197.0M | $221.1M | $247.9M | $272.3M | $297.9M |
| Total liabilities | $61.1M | $59.2M | $62.5M | $69.5M | $76.5M | $85.2M |
| Shareholders' equity | $112.6M | $137.8M | $158.6M | $178.4M | $195.8M | $212.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology